Cyborg | Designer-Babies | Futurism | Futurist | Immortality | Longevity | Nanotechnology | Post-Human | Singularity | Transhuman

HAIFA, Israel — Pluristem Therapeutics, Inc. , a leading developer of placenta-based cell therapies, announced today that Company executives are actively participating in a series of meetings in Washington …

Follow this link:
Pluristem and the Alliance for Regenerative Medicine Advocate for Industry Advancement in Washington D.C.

NEW YORK (TheStreet) –Aastrom Biosciences (ASTM) soared Monday after the company announced its acquisition ofSanofi’sCell Therapy and Regenerative Medicine, or CTRM, business for $6.5 million.

Aastrom will pay $4 million in cash and $2.5 million in a promissory note for the business. The company expects the acquisition to close in approximately three weeks.

The acquisition gives Aastromglobal commercial rights to three marketed autologous cell therapy products called Carticel, Epicel and MACI.Revenues of those three products totaled $44 million in 2013. Aastrom will also acquiremanufacturing and production centers in the U.S. and Denmark.

The stock was up 32.1% to $46.5 at 11:15 a.m., by which point it had eclipsed its average volume of380,200 with more than 1.6 million shares traded for the day. Aastrom hit a high of $4.95 for the day as of that time.

“The acquisition of Sanofi’s CTRM business is a transformative transaction that positions Aastrom as a fully-integrated global regenerative medicine company,” said Aastrom President and CEO Nick Colangelo in a statement. “The CTRM business brings us global manufacturing, marketing and sales capabilities that are structured to support the current portfolio of marketed products as well as our future product development plans. This transaction also provides us with a platform to generate operating income to support the development of our high-potential pipeline products and continued growth through additional strategic transactions.”

“Sanofi’s CTRM business, a pioneering organization with more than 20 years of experience in cell therapy and regenerative medicine, developed and marketed some of the first regenerative medicine products in the world,” he continued. “We look forward to working with the talented CTRM team to build Aastrom into the leading cell therapy company in the regenerative medicine field.”

ASTM data by YCharts

Continue reading here:
Why Aastrom Biosciences (ASTM) Stock Is Soaring Today

TOKYO–(BUSINESSWIRE)– Shiseido Co., Ltd. (TOKYO:4911) announces plans to open the Shiseido Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center, located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan, will centralize research and development on hair regenerative medicine with an aim toward commercialization. Regenerative medicine in Japan is an emerging …

Excerpt from:
Shiseido Opens Research Facility Dedicated to Hair Regeneration

Shiseido Co., Ltd. (TOKYO:4911) announces plans to open the Shiseido Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center, located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan, will centralize research and development on hair regenerative medicine with an aim toward commercialization.

Regenerative medicine in Japan is an emerging industry which the government aims to foster through new legislation and revisions to existing law as part of economic reform strategies, in order to advance in this field. Shiseido has a long history of conducting comprehensive research and working towards commercialization of the regenerative medicine for hair.

Shiseido’s hair regenerative medicine technology

With the goal of clinical application of regenerative medicine to treat alopecia and thinning hair, Shiseido concluded a technical collaboration agreement in July 2013 with a Canadian bio-venture company RepliCel Life Sciences Inc. (hereinafter referred to as “RepliCel”) acquiring an exclusive geographic license to use RepliCel Hair-01 (RCH-01) hair regeneration technology in Asia, including Japan.

RCH-01 has been developed over 10 years of scientific research, and safe application in humans has been validated by RepliCel’s phase 1 clinical trial. RepliCel has patents issued for hair follicle mesenchymal stem cells and their usage in Japan, the United States, Australia and the EU. RCH-01 is an “autologous cell transplantation technology,” in which specific cells(1) isolated from the hair follicles(2) taken from the scalp of a patient are cultured and implanted (injected) into the balding scalp area, potentially stimulating residing hair follicles and promoting new growth in the balding scalp area. (1) Dermal Sheath Cup cells, which are believed to play an important role in promoting hair growth (2) A hair follicle is a skin organ composed of various cell types that support hair growth and structure.

Kobe Biomedical Innovation Cluster

Follow this link:
Shiseido Cell-Processing and Expansion Center to be opened in Kobe, Japan

Reprint Permissions

A single copy of these materials may be reprinted for noncommercial personal use only. “Mayo,” “Mayo Clinic,” “MayoClinic.com,” “EmbodyHealth,” “Enhance your life,” and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.

See the rest here:
Center for Regenerative Medicine – Mayo Clinic Research

ANN ARBOR, Mich. — Aastrom Biosciences, Inc. , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced …

The rest is here:
Aastrom Announces Definitive Agreement to Acquire Sanofi's Cell Therapy and Regenerative Medicine Business

A significant breakthrough could revolutionize surgical practice and regenerative medicine. A team led by Ludwik Leibler from the Laboratoire Matire Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris Diderot and Paris 13), has just demonstrated that the principle of adhesion by aqueous solutions of nanoparticles can be used in vivo to repair soft-tissue organs and tissues. This easy-to-use gluing method has been tested on rats. When applied to skin, it closes deep wounds in a few seconds and provides a esthetic, high quality healing. It has also been shown to successfully repair organs that are difficult to suture, such as the liver. Finally, this solution has made it possible to attach a medical device to a beating heart, demonstrating the method’s potential for delivering drugs and strengthening tissues. This work has just been published on the website of the journal Angewandte Chemie.

In an issue of Nature published in December last year, a team led by Ludwik Leibler presented a novel concept for gluing gels and biological tissues using nanoparticles. The principle is simple: nanoparticles contained in a solution spread out on surfaces to be glued bind to the gel’s (or tissue’s) molecular network. This phenomenon is called adsorption. At the same time the gel (or tissue) binds the particles together. Accordingly, myriad connections form between the two surfaces. This adhesion process, which involves no chemical reaction, only takes a few seconds. In their latest, newly published study, the researchers used experiments performed on rats to show that this method, applied in vivo , has the potential to revolutionize clinical practice.

In a first experiment, the researchers compared two methods for skin closure in a deep wound: traditional sutures, and the application of the aqueous nanoparticle solution with a brush. The latter is easy to use and closes skin rapidly until it heals completely, without inflammation or necrosis. The resulting scar is almost invisible.

In a second experiment, still on rats, the researchers applied this solution to soft-tissue organs such as the liver, lungs or spleen that are difficult to suture because they tear when the needle passes through them. At present, no glue is sufficiently strong as well as harmless for the organism. Confronted with a deep gash in the liver with severe bleeding, the researchers closed the wound by spreading the aqueous nanoparticle solution and pressing the two edges of the wound toget her. The bleeding stopped. To repair a sectioned liver lobe, the researchers also used nanoparticles: they glued a film coated with nanoparticles onto the wound, and stopped the bleeding. In both situations, organ function was unaffected and the animals survived.

“Gluing a film to stop leakage” is only one example of the possibilities opened up by adhesion brought by nanoparticles. In an entirely different field, the researchers have succeeded in using anoparticles to attach a biodegradable membrane used for cardiac cell therapy, and to achieve this despite the substantial mechanical constraints due to its beating. They thus showed that it would be possible to attach various medical devices to organs and tissues for therapeutic, repair or mechanical strengthening purposes.

This adhesion method is exceptional because of its potential spectrum of clinical applications. It is simple, easy to use and the nanoparticles employed (silica, iron oxides) can be metabolized by the organism. It can easily be integrated into ongoing research on healing and tissue regeneration and contribute to the development of regenerative medicine.

Story Source:

The above story is based on materials provided by INSERM (Institut national de la sant et de la recherche mdicale). Note: Materials may be edited for content and length.

View original post here:
Innovative strategy to facilitate organ repair

Los Angeles, CA (PRWEB) April 19, 2014

MetroMD, Institute of Regenerative Medicine enunciates to offer laser skin resurfacing treatment to combat aging and deal with skin imperfections. Laser Skin treatment, alternatively known as DOT therapy is a new breakthrough in wellness industry. The revolutionary laser therapy is applied all over the face and neck to do away with frown lines, wrinkles, acne scars, unwanted folds, and sagging skin. The same laser is used to remove hyper pigmentation on the back of hands and tighten the loose, weathered skin along the forearms and thighs. The prominent institute in regenerative medicine industry runs a licensed Laser Skin Resurfacing Clinic Los Angeles. Source: Devin Stone, METROMD.

The breakthrough in the medical industry HGH, CO2 Fractional Laser, and Stem Cells are used together to combat the signs of aging, and overexposure to sunlight and to those who suffer from premature aging. Once administered the therapy increases blood flow, nearly vanishes the dark pigmented stains from UV rays,” says Dr. Alex Martin, Medical Director at the Institute. The skins appearance becomes healthy and rejuvenated within three weeks of the procedure. The unique amalgamation of FDA approved CO2 Laser, Human Growth Hormone and Stem Cell therapies work wonder on skin to make it radiant and youthful even after the age of forty. Over the last decade, many breakthroughs have occurred at the beginning of 21st Century to deal with the multitude of skin woes without having the need to undergo any conventional surgical techniques and longer rehabilitation period.

About MetroMD MetroMD is a Los Angeles based clinical institute and a leading provider of PRP, Stem Cell Therapy, Botox, Laser Skin Resurfacing and other innovative treatments. The institute treats the patients with latest technology to treat aging, improve sports performance, texture of hair, nail, libido enhancement with HGH therapy. All the treatments are FDA approved and hence considered safe. The institute runs licensed Stem Cell Therapy clinic in Los Angeles. HGH treatment is clinically proven to treat Human Growth Deficiency with excellent results.

MetroMD Institute of Regenerative Medicine 7080 Hollywood Blvd, Suite 804 Los Angeles, CA 90028 (323) 285-5300

See the article here:
Los Angeles Based Clinic MetroMD Expands Its Treatments of DOT Therapy, One of the Best Laser Skin Treatments for …



Regenerative Medicine, Younger skin, hair regrowth, PRP, stem cells, stretch marks
This presentation discuss using your own cells and platelets to regenerate your body for a healthier and younger you, whether it is for your face, neck, hand…

By: BangkokStemCells

Read the original here:
Regenerative Medicine, Younger skin, hair regrowth, PRP, stem cells, stretch marks – Video



Explore Personalized Medicine, with Sonia Arrison
Explore Personalized Medicine Sonia Arrison, Policy Analyst Author Examples of the kind of regenerative medicine that will ultimately eradicate cancer, AID…

By: Big Think Edge

Excerpt from:
Explore Personalized Medicine, with Sonia Arrison – Video



The Australian Regenerative Medicine Institute (ARMI) – Brazil
The Australian Regenerative Medicine Institute offers many opportunities for research.

By: MonashUniFMNHS

Link:
The Australian Regenerative Medicine Institute (ARMI) – Brazil – Video



The Australian Regenerative Medicine Institute (ARMI)
The Australian Regenerative Medicine Institute offers many opportunities for research.

By: MonashUniFMNHS

More here:
The Australian Regenerative Medicine Institute (ARMI) – Video

RANCHO CORDOVA, Calif. — Cesca Therapeutics Inc. , an autologous cell-based regenerative medicine company, today announced the restructuring of its sales, marketing and technical support organization …

View post:
Cesca Therapeutics Announces Sales & Marketing Organizational Restructuring and the Appointment of Industry Veteran …

Washington (PRWEB) April 15, 2014

Research that resulted in the first stem cells that are pluripotentthose that have the potential to differentiate into almost any cell in the bodywill be the backdrop for a discussion about trends in regulation in the field of regenerative medicine at the DIA 2014 50th Annual Meeting, June 15 to 19 in San Diego.

Chaired by Shinji Miyake, professor of clinical research for the Keio University School of Medicine in Japan, the session Pioneering Regenerative Medicine: Trends in Regulations for New Therapy will introduce the worlds first clinical research of induced pluripotent stem (iPS) cell products, conducted in Japan, and review updated regulatory guidance to bring regenerative medicine to patients who need healthy tissue or organs. The session will be held June 16 at 8:30 a.m. in the San Diego Convention Center.

iPS cells are stem cells that can be generated directly from adult cells. These cells can multiply indefinitely and represent a single source of cells, such as heart, neural, pancreatic and liver, that can be used to replace damaged cells.

In 2006, Japanese physician and researcher Shinya Yamanaka led a team to generate iPS cells from adult mouse tissue using gene therapy. This work led to a Nobel Prize in Physiology or Medicine in 2012 for the discovery that mature cells can be reprogrammed to become pluripotent.

We are honored to host pioneers of this unique field of medicine at the DIA Annual Meeting to share their experiences in the planning of the first clinical research of iPS cell productswhich have the ability to enhance research worldwide, said Barbara L. Kunz, DIA global chief executive. Their expert knowledge of issues and solutions in the application of the regenerative therapies will benefit all who advocate for and drive innovative medicine.

The session will also feature a presentation about the application of iPS cells to retinal diseases by Masayo Takahashi, project leader for the RIKEN Center for Developmental Biology in Japan, along with a European Medicines Agency (EMA) presentation by Dariusz Sladowski, researcher and member of the Committee for Advanced Therapies at EMA.

ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIAs network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Pa., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit http://www.diahome.org.

ABOUT DIAs 2014 50th ANNUAL MEETING: Celebrate the Past Invent the Future is the largest multidisciplinary event that brings together a community of life sciences professionals at all levels and across all disciplines involved in the discovery, development and life cycle management of medical products. The meeting aims to foster innovation that will lead to the development of safe and effective medical products and therapies for patients. For more information, visit http://www.diahome.org/dia2014.

Continued here:
Pioneers in Regenerative Therapy to Discuss New Trends in Stem Cell Medicine

BURLINGTON, Mass., April 15, 2014 /PRNewswire/ –inVentiv Health Clinical, a leading global supplier of drug development services, announced today that it has been selected for an osteoarthritis Investigational New Drug Application (IND) by the innovative regenerative medicine biotechnology company IntelliCell BioSciences, Inc., (OTCQB:SVFC). IntelliCell will be studying the use of adult autologous vascular cells from blood vessels in adipose tissue to treat osteoarthritis of the knee.

The principal investigator is Dr. James Andrews, an orthopedic surgeon known internationally for his scientific and clinical research into knee, shoulder and elbow injuries. Dr. Andrews is a founding member of the American Sports Medicine Institute, author of numerous scientific articles and books and founding partner and medical director at the Andrews Institute in Gulf Breeze, Florida.

inVentiv Clinical will work with Dr. Andrews to develop investigational clinical study protocols and will serve as the Clinical Research Organization (CRO) on trials conducted at the Pensacola Center of the Andrews Institute.

IntelliCell’s technology for isolating stromal vascular fraction cells from the vasculature of adipose tissue has been used to treat more than 60 knees. IntelliCell’s Chief Executive Officer, Dr. Steven Victor, said this is what we believe will be the first of several clinical trials for the biotech company studying the use of its technology in treating a variety of diseases and conditions.

“inVentiv Clinical has extensive therapeutic experience in general pain and osteoarthritis programs and a focus on partnering with innovative bioscience companies,” said Raymond Hill, President of inVentiv Health Clinical. “We are looking forward to our work with Dr. Andrews and contributing to advances in the treatment of osteoarthritis in knees.”

inVentiv Health Clinical offers clients a full range of clinical research services supported by a global infrastructure, therapeutic expertise, and unmatched commitment to quality. For pharmaceutical, biotechnology, generic drug, and medical device companies, inVentiv conducts Phase I-III clinical trials, Phase IV late stage post-approval programs, as well as offering staffing, bioanalytical and regulatory services.

IntelliCell’s IND study will focus on proving the company’s patented technology of Ultrasonic Cavitation as a method of producing stromal vascular fraction cells as a new approach and improvement on current treatment which in the worst cases can involve surgery.

About 75% of people over 70 years of age show changes consistent with osteoarthritis and symptoms such as pain, joint stiffness and joint deformities. Osteoarthritis affects more than 25 million people in the United States alone.

Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function by replacing damaged tissue and/or by stimulating the body’s own repair mechanisms to heal previously irreparable tissues or organs.

IntelliCell is planning an in-human clinical trial in late 2014 to study if the IntelliCell vascular fraction cells may demonstrate measurable benefits for patients suffering from this debilitating condition.

Read more:
inVentiv Health Clinical Engaged by IntelliCell Biosciences, a Regenerative Medicine Company, as Clinical Research …



3D Tissue Stimulation for Regenerative Medicine
See how a unique partnership between Loughborough University and Bose is advancing the field of tissue engineering and regenerative medicine.

By: ajf3015

Continue reading here:
3D Tissue Stimulation for Regenerative Medicine – Video



iPSCs for cardiovascular diseases
This video highlights application of pluripotent stem cells for cardiac disease modeling, drug discovery, and regenerative medicine.

By: StanfordUniversity

Follow this link:
iPSCs for cardiovascular diseases – Video



Custom Compounding and Regenerative Medicine – The Kohana Difference
Description.

By: KohanaRx

Visit link:
Custom Compounding and Regenerative Medicine – The Kohana Difference – Video



USC Master of Science in Stem Cell Biology and Regenerative Medicine
The Master of Science degree program is the first in stem cell biology and regenerative medicine in California, and one of only three in the U.S. The one-yea…

By: USCKeck

The rest is here:
USC Master of Science in Stem Cell Biology and Regenerative Medicine – Video

IntelliCell BioSciences, Inc. , a regenerative medicine company utilizing adult autologous stomovascular cells derived from the blood vessels found in adipose tissue, announced today that it has engaged …

See the article here:
IntelliCell BioSciences Has Engaged inVentiv Clinical as CRO for Osteoarthritis IND Lead by Dr. James Andrews



FireFox! Start Your Own Web Hosting Company
Web Hosting Advertise Here $10 a Month Affordable web-hosting
Pierre Teilhard De Chardin




Designer Children | Prometheism | Euvolution | Transhumanism

Sign up below for the Prometheism / Designer Children Discussion Forum

Subscribe to prometheism-pgroup

Powered by us.groups.yahoo.com